Related Experiment Video
Updated: Oct 22, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Combined computational and intracellular peptide library screening: towards a potent and selective Fra1 inhibitor
Miao Yu1, Lila Ghamsari2, Jim A Rotolo2
1Department of Biology & Biochemistry, University of Bath Claverton Down Bath BA2 7AY UK j.mason@bath.ac.uk +44 (0)1225386867.
Abstract:
To date, most research into the inhibition of oncogenic transcriptional regulator, Activator Protein 1 (AP-1), has focused on heterodimers of cJun and cFos. However, the Fra1 homologue remains an important cancer target. Here we describe library design coupled with computational and intracellular screening as an effective methodology to derive an antagonist that is selective for Fra1 relative to Jun counterparts. To do so the isCAN computational tool was used to rapidly screen >75 million peptide library members, narrowing the library size by >99.8% to one accessible to intracellular PCA selection. The resulting 131 072-member library was predicted to contain high quality binders with both a high likelihood of target engagement, while simultaneously avoiding homodimerization and off-target interaction with Jun homologues. PCA screening was next performed to enrich those members that meet these criteria. In particular, optimization was achieved via inclusion of options designed to generate the potential for compromised intermolecular contacts in both desired and non-desired species. This is an often-overlooked prerequisite in the conflicting design requirement of libraries that must be selective for their target in the context of a range of alternative potential interactions. Here we demonstrate that specificity is achieved via a combination of both hydrophobic and electrostatic contacts as exhibited by the selected peptide (Fra1W). In vitro analysis of the desired Fra1-Fra1W interaction further validates high Fra1 affinity (917 nM) yet selective binding relative to Fra1W homodimers or affinity for cJun. The isCAN → PCA based multidisciplinary approach provides a robust screening pipeline in generating target-specific hits, as well as new insight into rational peptide design in the search for novel bZIP family inhibitors.
Insights
Researchers developed a new method to find peptide drugs that target Fra1, an important protein in cancer. This approach uses computational screening and intracellular selection to create specific inhibitors, like the peptide Fra1W, which shows high affinity for Fra1.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Activating Protein 1 (AP-1) is a key transcriptional regulator in cancer, with cJun and cFos being well-studied components.
- The Fra1 homologue is an important, yet less explored, target for cancer therapies.
- Developing selective inhibitors for AP-1 family members is challenging due to potential off-target interactions.
Purpose of the Study:
- To develop a novel methodology for designing peptide antagonists selective for the Fra1 protein.
- To identify a specific inhibitor for Fra1, distinct from its Jun counterparts.
- To gain insight into rational peptide design for targeting bZIP family proteins.
Main Methods:
- Utilized the isCAN computational tool to screen over 75 million peptide library members.
- Employed intracellular Protein-Complementation Assay (PCA) selection to enrich for high-quality binders.
- Incorporated design strategies to ensure target engagement and selectivity, avoiding homodimerization and off-target interactions.
Main Results:
- Successfully narrowed down the peptide library by over 99.8% using computational screening.
- Identified a selective peptide inhibitor, Fra1W, which binds Fra1 with high affinity (917 nM).
- Demonstrated that Fra1W achieves specificity through a combination of hydrophobic and electrostatic interactions, avoiding significant binding to cJun.
Conclusions:
- The isCAN and PCA-based approach provides a robust pipeline for generating target-specific peptide inhibitors.
- The study offers new insights into rational peptide design for selective inhibition of bZIP family proteins.
- Fra1W represents a promising lead compound for targeting Fra1 in cancer therapy.
More Related Videos
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020